Cargando…

Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer

Impressive responses have been observed in patients with cancer treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies through disinhibiting the immune system. However, tumors possess complex immunosuppressive tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xinge, Li, Xiqing, Wang, Hongqiang, Yu, Zhenghong, Zhu, Yu, Gao, Yanzheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617297/ https://www.ncbi.nlm.nih.gov/pubmed/31334002 http://dx.doi.org/10.1016/j.jbo.2018.11.001

Ejemplares similares

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor
por: Cai, Yu, et al.
Publicado: (2020)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer
por: Li, Yingjue, et al.
Publicado: (2023)

B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
por: Lu, Huimin, et al.
Publicado: (2020)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection
por: Pillinger, Genevra, et al.
Publicado: (2016)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Pd-catalyzed γ-arylation of γ,δ-unsaturated O-carbamates via an unusual haptotropic rearrangement
por: Royal, Titouan, et al.
Publicado: (2018)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
por: Lauder, Sarah N., et al.
Publicado: (2021)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
por: Carter, M J, et al.
Publicado: (2017)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
por: Wang, Liang-Chuan S, et al.
Publicado: (2015)

Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
por: Zhu, Jingyu, et al.
Publicado: (2019)

More Paths to PI3Kγ
por: Stephens, Len, et al.
Publicado: (2013)

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
por: Xie, Chengying, et al.
Publicado: (2017)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Systematic Review of Published Cases of Primary Epithelioid Sarcoma of the Spine
por: Hu, Weiran, et al.
Publicado: (2023)

Does the Microflora of Surgery Site Infection Change After Prophylactic Use of Vancomycin Powder in the Spine Surgery
por: Hu, Weiran, et al.
Publicado: (2023)

Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
por: Guan, Ying, et al.
Publicado: (2017)

Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
por: Yang, Rui, et al.
Publicado: (2022)

PI3Kδ过度活化综合征一例
Publicado: (2021)

Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ
por: Cevey, Ágata C., et al.
Publicado: (2021)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
por: Wang, Zhongwang, et al.
Publicado: (2023)

Lifespan of γ/δ T Cells
por: Tough, David F., et al.
Publicado: (1998)

New γ-Halo-δ-lactones and δ-Hydroxy-γ-lactones with Strong Cytotoxic Activity
por: Kamizela, Angelika, et al.
Publicado: (2019)

The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells
por: Xu, Yanning, et al.
Publicado: (2022)

Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures
por: Hu, Weiran, et al.
Publicado: (2020)

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qbe3uh7mtb1popomehl0qaacba